Left ventricular hypertrophy in renal disease: beyond preload and afterload
Author:
- 1 April 2009
- journal article
- Published by Elsevier in Kidney International
- Vol. 75 (8) , 771-773
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressureKidney International, 2009
- Toward MicroRNA–Based Therapeutics for Heart DiseaseCirculation Research, 2008
- Sirolimus treatment of left ventricular hypertrophy: who, and when?European Heart Journal, 2008
- Endothelial-to-mesenchymal transition contributes to cardiac fibrosisNature Medicine, 2007
- mTOR Pathway as a Target in Tissue HypertrophyAnnual Review of Pharmacology and Toxicology, 2007
- Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic CardiomyopathyHypertension, 2006
- Ras, PI3-kinase and mTOR signaling in cardiac hypertrophyCardiovascular Research, 2004
- Hypertrophy of the HeartCirculation, 2004
- Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in MiceCirculation, 2003
- Myocardial hypertrophy in rats with renal insufficiencyKidney International, 1985